Codagenix lands $20 mln Series B

Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding.

14 January 2020•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles